EGFR and non-small cell lung carcinoma: The biological rationale behind the effect of EGFR mutation status on the benefit of atezolizumab may be related to the fact that EGFR-mutant NSCLC subpopulations have more active escape/resistance pathways, which may limit the efficacy of atezolizumab in this context (69).